期刊文献+

伏立康唑治疗4例早产儿侵袭性真菌感染 被引量:4

原文传递
导出
摘要 目的 总结伏立康唑治疗早产儿侵袭性真菌感染的疗效及安全性. 方法 2010年1月至2011年1月,北京军区总医院附属八一儿童医院极早产儿重症监护中心收治侵袭性真菌感染早产儿4例,均使用伏立康唑治疗.总结4例患儿的救治过程及效果,结合文献分析伏立康唑治疗早产儿侵袭性真菌感染的疗效及安全性. 结果 4例患儿胎龄27-3~34周,均为男婴,出生体重1 030~1 940 g.均曾全身性使用广谱抗生素治疗,预防性或治疗性使用氟康唑抗真菌治疗,但依然血培养阳性,近平滑假丝酵母菌2例,白假丝酵母菌和克柔假丝酵母菌各1例.遂给予静脉滴注伏立康唑(4 mg/kg,每12小时1次)治疗14~28 d.治疗后,全部患儿真菌血培养转阴,G试验阴性.2例患儿出现丙氨酸转氨酶升高(分别升高至79和51 U/L),停药后缓解;3例患儿发生早产儿视网膜病.未出现中枢神经系统并发症,无电解质紊乱、肾功能损害等情况发生,未发现较严重的药物不良反应. 结论 伏立康唑治疗早产儿侵袭性真菌感染有效,且短期内相对安全.
出处 《中华围产医学杂志》 CAS 北大核心 2014年第2期126-127,共2页 Chinese Journal of Perinatal Medicine
  • 相关文献

参考文献7

  • 1高宁舟,沈杰,宋钟娟,刘奕芳.三唑类抗真菌药物治疗药物监测的研究进展[J].药学服务与研究,2009,9(5):336-339. 被引量:7
  • 2王汝龙.三唑类抗深部真菌药的临床药学进展[J].临床药物治疗杂志,2007,5(1):1-7. 被引量:8
  • 3Frankenbusch K, Eifinger F, Kribs A, et al. Severe primary cutaneous aspergillosis refractory to amphotericin B and the successful treatment with systemic voriconazole in two premature infants with extremely low birth weight[J].J Perinatol,2006, 26:511-514.
  • 4Santos RP, Sanchez PJ, Mejias A, et al. Successful medical treatment of cutaneous aspergillosis in a premature infant using liposomal amphotericin B, vorieonazole and micafungin[J]. Pediatr Infect Dis J, 2007, 26:364-366.
  • 5Kohli V, Taneja V, Sachdev P, et al. Voriconazole in newborns[J]. Indian Pediatr, 2008, 45:236-238.
  • 6黄捷婷,李秋平,封志纯.早产儿侵袭性真菌感染的现状及预防进展[J].中华儿科杂志,2011,49(12):911-914. 被引量:7
  • 7Manzoni P, Stolfi I, Messner H, et al. Bovine lactoferrin prevents invasive fungal infections in very low birth weight infants: a randomized controlled trial[J]. Pediatrics, 2012, 129:116-123.

二级参考文献55

  • 1陈丽娟.HPLC测定人血浆中伊曲康唑的浓度[J].华西药学杂志,2006,21(3):293-295. 被引量:10
  • 2Singh N. Trends in the epidemiology of opportunistic fungal infections:predisposing factors and the impact of antimicrobiaI use practices[J]. Clin Infect Dis,2001,33(15) : 1692- 1696.
  • 3Denning D W,Tueker R M,Hanson L H,et al. Treatment of invasive aspergillosis with itraconazole[J]. Am J Med, 1989, 86(6 Pt2) :791-800.
  • 4Tucker R M,Denning D W,Arathoon E G,et al. Itraconazote therapy for nonmeningeal coccidioidomycosis: clinical and lahoratory observations [J]. J Am Acad Dermatol, 1990, 23(3Pt 2):593 -601.
  • 5Denning D W, Tucker R M, Hanson I. H, et al. Itraconazole therapy for cryptococcal meningitis and cryptococcosis[J].Arch Intern Med,1989,149(10) :2301-2308.
  • 6Tricot G,Joosten E, Boogaerts M A, et al. Retoconazole vs itraconazole for antifungal prophylaxis in patients with severe granulocytopenia: preliminary results of two nonrandomized studies[J].Rev Infect Dis, 1987,9(Suppl 1):S94-S99.
  • 7Service R F. Pharmacogenomics. Going from genome to pill [J]. Science, 2005,308(5730):1858-1860.
  • 8Trifilio S, Pennick G, Pi J, et al. Monitoring plasma voriconazole levels may be necessary to avoid subtherapeutie levels in hematopoietic stem cell transplant recipients[J]. Cancer,2007,109(8) : 1532 -1535.
  • 9Trifilio S, Ortiz R, Pennick G, et al. Voriconazole therapeutic drug monitoring in allogeneic hematopoietic stem cell transplant recipients[J].Bone Marrow Transplant, 2005,35(5): 509 -513.
  • 10Boyd A E,Modi S, Howard S J, et al. Adverse reactions to voriconazole[J].Clin Infect Dis,2004,39(15) : 1241- 1244.

共引文献19

同被引文献25

引证文献4

二级引证文献9

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部